Literature DB >> 8700545

Structurally altered Evi-1 protein generated in the 3q21q26 syndrome.

S Ogawa1, M Kurokawa, T Tanaka, K Mitani, J Inazawa, A Hangaishi, K Tanaka, Y Matsuo, J Minowada, T Tsubota, Y Yazaki, H Hirai.   

Abstract

Overexpression of the Evi-1 gene appears to be a consistent feature of the 3q21q26 syndrome, an association of myeloid leukemias/myelodysplastic syndrome with a specific chromosomal aberration involving both 3q21 and 3q26, such as t(3;3)(q21;q26) or inv(3)(q21q26). The rearrangement in 3q26 has been reported to occur near the Evi-1 locus, implicating that it is the critical gene deregulated in the 3q21q26 syndrome. Here we present a structural abnormality of Evi-1 protein in a case with the 3q21q26 syndrome. In this case carrying typical inv(3)(q21q26), the 3q26 breakpoint is located within an intron of the Evi-1 gene, and resulted in overexpression of normally unexpressed, an aberrant form of Evi-1 protein, in which the C-terminal 44 amino acids of wild-type Evi-1 protein were truncated and replaced by five amino acids. The truncated Evi-1 protein is shown to increase AP1 activity when expressed in NIH3T3 cells as its wild-type counterpart. We also show that the origin of this peculiar type of rearrangement of the Evi-1 gene is not an artifact during establishment of the cell line, but is the event that occurred in the primary leukemic cells. Our results strongly support that the primary target for the 3q21q26 syndrome is the Evi-1 gene, and provide the first evidence that the structurally altered Evi-1 gene may be involved in the 3q21q26 syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700545

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Evi1 regulates Notch activation to induce zebrafish hematopoietic stem cell emergence.

Authors:  Martina Konantz; Elisa Alghisi; Joëlle S Müller; Anna Lenard; Virginie Esain; Kelli J Carroll; Lothar Kanz; Trista E North; Claudia Lengerke
Journal:  EMBO J       Date:  2016-09-16       Impact factor: 11.598

2.  The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.

Authors:  M Kurokawa; K Mitani; T Yamagata; T Takahashi; K Izutsu; S Ogawa; T Moriguchi; E Nishida; Y Yazaki; H Hirai
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

3.  Meta-analysis identifies a MECOM gene as a novel predisposing factor of osteoporotic fracture.

Authors:  Joo-Yeon Hwang; Seung Hun Lee; Min Jin Go; Beom-Jun Kim; Ikuyo Kou; Shiro Ikegawa; Yan Guo; Hong-Wen Deng; Soumya Raychaudhuri; Young Jin Kim; Ji Hee Oh; Youngdoe Kim; Sanghoon Moon; Dong-Joon Kim; Heejo Koo; My-Jung Cha; Min Hye Lee; Ji Young Yun; Hye-Sook Yoo; Young-Ah Kang; Eun-Hee Cho; Sang-Wook Kim; Ki Won Oh; Moo Il Kang; Ho Young Son; Shin-Yoon Kim; Ghi Su Kim; Bok-Ghee Han; Yoon Shin Cho; Myeong-Chan Cho; Jong-Young Lee; Jung-Min Koh
Journal:  J Med Genet       Date:  2013-01-24       Impact factor: 6.318

4.  Molecular cytogenetic analyses of HIG, a novel human cell line carrying t(1;3)(p36.3;q25.3) established from a patient with chronic myelogenous leukemia in blastic crisis.

Authors:  Noriko Hosoya; Seishi Ogawa; Tohru Motokura; Akira Hangaishi; Lili Wang; Ying Qiao; Yasuhito Nannya; Mieko Kogi; Hisamaru Hirai
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

5.  Common sites of retroviral integration in mouse hematopoietic tumors identified by high-throughput, single nucleotide polymorphism-based mapping and bacterial artificial chromosome hybridization.

Authors:  Haifa Shen; Takeshi Suzuki; David J Munroe; Claudia Stewart; Lynn Rasmussen; Debra J Gilbert; Nancy A Jenkins; Neal G Copeland
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 6.  Evi1 forms a bridge between the epigenetic machinery and signaling pathways.

Authors:  Akihide Yoshimi; Mineo Kurokawa
Journal:  Oncotarget       Date:  2011-07

7.  Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.

Authors:  P O Pietarinen; T Pemovska; M Kontro; B Yadav; J P Mpindi; E I Andersson; M M Majumder; H Kuusanmäki; P Koskenvesa; O Kallioniemi; K Wennerberg; C A Heckman; S Mustjoki; K Porkka
Journal:  Blood Cancer J       Date:  2015-05-01       Impact factor: 11.037

8.  Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.

Authors:  Emilie A Bard-Chapeau; Dorota Szumska; Bindya Jacob; Belinda Q L Chua; Gouri C Chatterjee; Yi Zhang; Jerrold M Ward; Fatma Urun; Emi Kinameri; Stéphane D Vincent; Sayadi Ahmed; Shoumo Bhattacharya; Motomi Osato; Archibald S Perkins; Adrian W Moore; Nancy A Jenkins; Neal G Copeland
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

9.  Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.

Authors:  Niclas Björn; Tejaswi Venkata Satya Badam; Rapolas Spalinskas; Eva Brandén; Hirsh Koyi; Rolf Lewensohn; Luigi De Petris; Zelmina Lubovac-Pilav; Pelin Sahlén; Joakim Lundeberg; Mika Gustafsson; Henrik Gréen
Journal:  NPJ Syst Biol Appl       Date:  2020-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.